8310-4:JMD:#344990

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)	
)	Before the Examiner
Günther SCHMID, et al.)	
)	
Serial No. (unknown)	j j	
,)	Group Art Unit
Filed May 13, 2005)	•
	j j	May 13, 2005
IMPLANT, THERAPEUTIC)	
AGENT AND MICELLE	í	
MODIAL WIAD MICEPPE)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with Applicants' continuing duty of disclosure under 37 CFR §1.97 (b)(3), the following patents are brought to the attention of the United States Patent and Trademark Office and specifically to the attention of the Examiner assigned to the subject patent application. The submitted documents are listed on the attached PTO Form. A copy of any cited reference which is not a U.S. patent is enclosed herewith.

U.S. PATENT REFERENCES

Patent No.	Date	Inventor		
4,146,499	03/27/79	Rosano		

FOREIGN PATENT REFERENCES

DOCUMENT NUMBER	DATE	COUNTRY
WO 99/24490 A1	05/20/99	PCT
WO 99/38898 A1	08/05/99	PCT
WO 00/48660 A1	08/24/00	PCT
WO 03/028700 A2	04/10/03	PCT
EP 0 875 218 A2	11/04/98	EP
EP 0 373 867 A1	06/20/90	EP

CONCISE EXPLANATION OF NON-ENGLISH REFERENCES

A concise explanation of the relevance of the non-English language prior art patents under 37 CFR §1.98(a)(3), as presently understood by the individual designated in §1.56(c) as most knowledgeable about the content of the information is set forth below.

WO 99/38898 A1

This invention generally concerns a novel family of biocompatible surfactant copolymers having a wide range of uses, in particular in pharmaceutics and for synthesizing substances in dispersed state and for surface treatment of material or biomaterials. Said copolymers are characterized in that they comprise a hydrophobic sequence constituted by: either a homopolymer consisting of recurrent units corresponding to the general formula (I) in which: R₁ represents a C₁-C₆ alkyl group or a (CH₂)_m – COOR₃ group wherein m is an integer between 1 and 5 and R₃ represents a C₁-C₆ alkyl group; R₂ represents a C₁-C₆ alkyl group; and n is an integer between 1 and 5; or a statistic copolymer consisting of different recurrent units corresponding to formula

(I) as defined above; or finally a statistic copolymer consisting for the major part of units corresponding to formula (I) as defined above.

WO 00/48660 A1

This invention relates to an implant with a holding area for a therapeutic agent which can pass out through a permeation element. According to the invention, the permeation element is configured as an open-pored diffusion element whose pore walls are chemically modified in order to control the diffusion. This ensures accurate dosage.

This Information Disclosure Statement is being filed concurrently with the filing of the above-identified patent application. It is believed that no fee is required for submission of this Statement. Should any fee be required, please charge such fee to Deposit Account No. 23-3030.

Respectfully submitted,

James M. Durlacher, Reg. No. 28,840

Woodard, Emhardt, Moriarty, McNett

& Henry LLP

Bank One Center/Tower

111 Monument Circle, Suite 3700

Indianapolis, Indiana 46204-5137

(317) 634-3456



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 1 of 1				Atty. Docket No. 8310-4			Serial 30.0/535517				
				Applicant Günther SCHMID, et al.							
				Filing Date May 13, 2005			Group	Group			
	,				S. PAT	ENT DOCUM					
*Examiner Initial		DOCUMENT NUMBER	DA	LE		NAME	С	LASS	SUBCLASS	Filing Date If appropriate	2
		4,146,499	03/27/79		03/27/79 Rosano		252		186		
										· · · · · · · · · · · · · · · · · · ·	
		, ,									
					•						
									,		
				FORE	CIGN F	PATENT DOC	IIMI	ENTS			
		DOCUMENT NU			TE	COUNTRY		CLASS	SUBCLASS	Transl Yes	ation No
		WO 99/24490) A1	05/2	0/99	PCT		C08G	65/32	X	
		WO 99/38898	3 A 1	08/0	5/99	PCT		C08F	287/00		X
		WO 00/48660			4/00	PCT		A61M	31/00		X
		WO 03/02870		04/1		PCT		A61K	9/00	X	
		EP 0 875 218			04/98 0/90	EP EP	-	A61F	2/06	X	
		EP 0 373 867				PATENT LITE	RATI	A61M	31/00 MENTS	X	
Examiner Initials*	Cite No.1	Include name of th	e author (i	n CAPITA	AL LETTE	RS), title of the article	(when	appropriate), ti	itle of the item (book, n		T ²
mitiais			,	J	, p				,,,	,	
Examiner	L	.1				Date Consid	lered				
*Examiner: i	nitial if	reference considere	d, whethe	r or not	citation	is in conformance	with M	IPEP 609: Dr	aw line through cita	tion if not in	·
conformance a	and not	considered. Includ	e copy of	this for	m with n	ext communication	n to ap	plicant.			